In last trading session, 10x Genomics Inc (NASDAQ:TXG) saw 2.87 million shares changing hands with its beta currently measuring 1.89. Company’s recent per share price level of $12.10 trading at $0.03 or 0.25% at ring of the bell on the day assigns it a market valuation of $1.48B. That closing price of TXG’s stock is at a discount of -300.17% from its 52-week high price of $48.42 and is indicating a premium of 10.74% from its 52-week low price of $10.80.

For 10x Genomics Inc (TXG), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 2.47. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 5 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.29 in the current quarter.

10x Genomics Inc (NASDAQ:TXG) trade information

Upright in the green during last session for gaining 0.25%, in the last five days TXG remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $12.10 price level, adding 7.77% to its value on the day. 10x Genomics Inc’s shares saw a change of -15.74% in year-to-date performance and have moved 2.37% in past 5-day. 10x Genomics Inc (NASDAQ:TXG) showed a performance of -19.76% in past 30-days.

Wall Street analysts have assigned a consensus price target of 25 to the stock, which implies a rise of 51.6% to its current value. Analysts have been projecting 24 as a low price target for the stock while placing it at a high target of 46. It follows that stock’s current price would drop -98.35% in reaching the projected high whereas dropping to the targeted low would mean a loss of -98.35% for stock’s current value.

10x Genomics Inc (TXG) estimates and forecasts

This year revenue growth is estimated to rise 0.30% from the last financial year’s standing.

15 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 133.55M for the same. And 15 analysts are in estimates of company making revenue of 146.4M in the next quarter. Company posted 141.01M and 153.1M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -36.10% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 1.75% while estimates for its earnings growth in next 5 years are of 17.47%.

10x Genomics Inc (NASDAQ:TXG)’s Major holders

FMR LLC is the top institutional holder at TXG for having 13.01 million shares of worth $253.05 million. And as of 2024-06-30, it was holding 10.8971 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 10.19 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.5341 of outstanding shares, having a total worth of $198.18 million.

On the other hand, ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 8.25 shares of worth $99.84 million or 7.62% of the total outstanding shares. The later fund manager was in possession of 3.25 shares on Sep 30, 2024 , making its stake of worth around $39.3 million in the company or a holder of 3.00% of company’s stock.